Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 286

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Androgens Regulate Phosphodiesterase Type 5 Expression and Functional Activity in Corpora Cavernosa

Morelli, Annamaria, Filippi, Sandra, Mancina, Rosa, Luconi, Michaela, Vignozzi, Linda, Marini, Mirca, Orlando, Claudio, Vannelli, Gabriella Barbara, Aversa, Antonio, Natali, Alessandro, Forti, Gianni, Giorgi, Mauro, Jannini, Emmanuele A., Ledda, Fabrizio, Maggi, Mario·2004·Endocrinology
DOI 10.1210/en.2003-1699
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2003-1699

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Francis, 2001, Cyclic nucleotide phosphodiesterases: relating structure and function., Prog Nucleic Acid Res Mol Biol, 65, 1
  2. Schudt, 1999, Therapeutic potential of selective PDE inhibitors in asthma., Pulm Pharmacol Ther, 12, 123, 10.1006/pupt.1999.0182 · DOI
  3. Movsesian, 1999, β-Adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate., J Am Coll Cardiol, 34, 318, 10.1016/S0735-1097(99)00220-X · DOI
  4. Lin, 2003, Phosphodiesterases as therapeutic targets., Urology, 61, 685, 10.1016/S0090-4295(02)02439-1 · DOI
  5. Manganiello, 2003, Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized., Mol Pharmacol, 63, 1209, 10.1124/mol.63.6.1209 · DOI
  6. Francis, 1988, Purification of cGMP-binding protein phosphodiesterase from rat lung., Methods Enzymol, 159, 722, 10.1016/0076-6879(88)59067-5 · DOI
  7. Loughney, 1998, Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase., Gene, 216, 139, 10.1016/S0378-1119(98)00303-5 · DOI
  8. Stacey, 1998, Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5)., Biochem Biophys Res Commun, 247, 249, 10.1006/bbrc.1998.8769 · DOI
  9. Yanaka, 1998, Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene., Eur J Biochem, 255, 391, 10.1046/j.1432-1327.1998.2550391.x · DOI
  10. Lin, 2002, Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters., Int J Impot Res, 14, 15, 10.1038/sj.ijir.3900802 · DOI
  11. Corbin, 1999, Cyclic GMP phosphodiesterase-5: target of sildenafil., J Biol Chem, 274, 13729, 10.1074/jbc.274.20.13729 · DOI
  12. Lin, 2001, Identification and regulation of human PDE5A gene promoter., Biochem Biophys Res Commun, 280, 684, 10.1006/bbrc.2000.4220 · DOI
  13. Filippi, 2002, Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation., Int J Impot Res, 14, 295, 10.1038/sj.ijir.3900890 · DOI
  14. Filippi, 2002, Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis., Endocrinology, 143, 4271, 10.1210/en.2002-220384 · DOI
  15. Pinzani, 2001, Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology., Regul Pept, 99, 79, 10.1016/S0167-0115(01)00235-X · DOI
  16. Casini Raggi, 2002, Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa., Clin Cancer Res, 8, 419
  17. D’Amati, 2002, Type 5 phosphodiesterase expression in the human vagina., Urology, 60, 191, 10.1016/S0090-4295(02)01663-1 · DOI
  18. Giordano, 2001, Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain., Biochim Biophys Acta, 1539, 16, 10.1016/S0167-4889(01)00086-6 · DOI
  19. Filippi, 2002, Identification, localization and functional activity of oxytocin receptors in epididymis., Mol Cell Endocrinol, 193, 89, 10.1016/S0303-7207(02)00101-6 · DOI
  20. Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding., Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 · DOI · Paper page
  21. Moreland, 1998, Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells, Life Sci, 62, PL309, 10.1016/S0024-3205(98)00158-1 · DOI
  22. Maggi, 2000, Erectile dysfunction: from biochemical pharmacology to advances in medical therapy., Eur J Endocrinol, 143, 143, 10.1530/eje.0.1430143 · DOI
  23. Filippi, 2003, Effects of NCX 4050, a new NO donor, in rabbit and human corpus cavernosum., Int J Androl, 26, 101, 10.1046/j.1365-2605.2003.00403.x · DOI
  24. De Lean, 1978, Simultaneous analysis of families of sigmoidal curves: applications to biossay, radioligand assay, and physiological dose-response curves, Am J Physiol, 235, E97
  25. Shukla, 2003, Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure., Ann Thorac Surg 2003, 75, 1437, 10.1016/S0003-4975(02)04892-0 · DOI
  26. Lin, 2003, Isolation of two isoforms of phosphodiesterase 5 from rat penis., Int J Impot Res, 15, 129, 10.1038/sj.ijir.3900983 · DOI
  27. Kuthe, 2000, Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis., Eur Urol 2000, 38, 108
  28. Kotera, 1999, Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases., Eur J Biochem, 262, 866, 10.1046/j.1432-1327.1999.00450.x · DOI
  29. Traish, 1999, Effects of castration and androgen replacement on erectile function in a rabbit model., Endocrinology, 140, 1861, 10.1210/endo.140.4.6655 · DOI · Paper page
  30. Traish, 2003, Effects of medical or surgical castration on erectile function in an animal model., J Androl, 24, 381, 10.1002/j.1939-4640.2003.tb02686.x · DOI
  31. Guay, 2001, Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors., J Androl, 22, 793, 10.1002/j.1939-4640.2001.tb02582.x · DOI · Paper page
  32. Yassin, 2003, Combination therapy of tadalafil and testosterone in hypogonadal non-responders, Int J Impot Res S, 6, S27
  33. Penson, 1996, Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat., Biol Reprod, 55, 567, 10.1095/biolreprod55.3.567 · DOI
  34. Mills, 1999, The role of androgens in the erectile response: A 1999 Perspective., Mol Urol, 3, 75
  35. Mills, 1999, Androgenic maintenance of the erectile response in the rat., Steroids, 64, 605, 10.1016/S0039-128X(99)00040-9 · DOI
  36. Zitzmann, 2001, Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs., Eur J Endocrinol, 144, 183, 10.1530/eje.0.1440183 · DOI · Paper page
  37. Shirozu, 1995, Penile tumescence in the human fetus at term—a preliminary report., Early Hum Dev, 41, 159, 10.1016/0378-3782(95)01618-D · DOI
  38. Bancroft, 1983, Changes in erectile responsiveness during androgen replacement therapy., Arch Sex Behav, 12, 59, 10.1007/BF01542116 · DOI
  39. Wegner, 1995, Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double-blind cross over trial., Int J Impot Res, 7, 233
  40. Martinez-Pineiro, 1998, Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction., Eur Urol, 34, 350, 10.1159/000019754 · DOI

Cited by

See all 286

Metadata

Authors
Morelli, A., Filippi, S., Mancina, R., Luconi, M., Vignozzi, L., Marini, M., Orlando, C., Vannelli, G. B., Aversa, A., Natali, A., Forti, G., Giorgi, M., Jannini, E. A., Ledda, F., & Maggi, M.
Venue
Endocrinology
Publisher
The Endocrine Society
Published
2004-05-01
Volume
145
Issue
5
Pages
2253-2263
ISSN
  • 0013-7227
  • 1945-7170
DOI
10.1210/en.2003-1699
Cited by
286
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.